Sigvotatug vedotin is a monoclonal antibody conjugated commercialized by Pfizer, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sigvotatug vedotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sigvotatug vedotin is expected to reach an annual total of $29 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sigvotatug vedotin Overview
Sigvotatug vedotin (SGNB-6A) is under development for the treatment of solid tumors including non-small cell lung cancer (NSCLC), adenocarcinoma of the gastroesophageal junction, head and neck squamous cell cancer (HNSCC), HER2 negative breast cancer, esophageal squamous cell carcinoma, ovarian cancer, esophageal cancer cutaneous squamous cell cancer (SCC), exocrine pancreatic adenocarcinoma, bladder cancer, cervical cancer and gastric cancer. It is administered through intravenous route. It is an vedotin-based ADC. The drug candidate comprises monoclonal antibody conjugated with monomethyl auristatin E (MMAE). It acts by targeting integrin beta 6.
Pfizer Overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$58,496 million for the fiscal year ended December 2023 (FY2023), a decrease of 41.7% over FY2022. The operating loss of the company was US$929 million in FY2023, compared to an operating profit of US$36,237 million in FY2022. In FY2023, the company recorded a net margin of 3.6%, compared to a net margin of 31.3% in FY2022.
The company reported revenues of US$13,283 million for the second quarter ended June 2024, a decrease of 10.7% over the previous quarter.
For a complete picture of Sigvotatug vedotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.